These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 33481032)

  • 1. Assessment of a Clinical Trial-Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Coquet J; Bievre N; Billaut V; Seneviratne M; Magnani CJ; Bozkurt S; Brooks JD; Hernandez-Boussard T
    JAMA Netw Open; 2021 Jan; 4(1):e2031730. PubMed ID: 33481032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
    Guinney J; Wang T; Laajala TD; Winner KK; Bare JC; Neto EC; Khan SA; Peddinti G; Airola A; Pahikkala T; Mirtti T; Yu T; Bot BM; Shen L; Abdallah K; Norman T; Friend S; Stolovitzky G; Soule H; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Xie Y; Aittokallio T; Zhou FL; Costello JC;
    Lancet Oncol; 2017 Jan; 18(1):132-142. PubMed ID: 27864015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational Phenomapping of Randomized Clinical Trials to Enable Assessment of their Real-world Representativeness and Personalized Inference.
    Thangaraj PM; Oikonomou EK; Dhingra LS; Aminorroaya A; Jayaram R; Suchard MA; Khera R
    medRxiv; 2024 May; ():. PubMed ID: 38798457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
    Terrisse S; Karamouza E; Parker CC; Sartor AO; James ND; Pirrie S; Collette L; Tombal BF; Chahoud J; Smeland S; Erikstein B; Pignon JP; Fizazi K; Le Teuff G;
    JAMA Oncol; 2020 Feb; 6(2):206-216. PubMed ID: 31830233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.
    Westgeest HM; Uyl-de Groot CA; van Moorselaar RJA; de Wit R; van den Bergh ACM; Coenen JLLM; Beerlage HP; Hendriks MP; Bos MMEM; van den Berg P; van de Wouw AJ; Spermon R; Boerma MO; Geenen MM; Tick LW; Polee MB; Bloemendal HJ; Cordia I; Peters FPJ; de Vos AI; van den Bosch J; van den Eertwegh AJM; Gerritsen WR
    Eur Urol Focus; 2018 Sep; 4(5):694-701. PubMed ID: 28753794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience.
    Afshar M; Evison F; James ND; Patel P
    Urol Oncol; 2015 Aug; 33(8):338.e1-7. PubMed ID: 26059077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of a Machine Learning Algorithm Using Electronic Health Record Data to Identify and Estimate Survival in a Longitudinal Cohort of Patients With Lung Cancer.
    Yuan Q; Cai T; Hong C; Du M; Johnson BE; Lanuti M; Cai T; Christiani DC
    JAMA Netw Open; 2021 Jul; 4(7):e2114723. PubMed ID: 34232304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
    Hernandez RK; Cetin K; Pirolli M; Quigley J; Quach D; Smith P; Stryker S; Liede A
    Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis.
    Koo KC; Lee JS; Kim JW; Han KS; Lee KS; Kim DK; Ha YS; Rha KH; Hong SJ; Chung BH
    BMC Cancer; 2018 Apr; 18(1):468. PubMed ID: 29695228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer.
    Heck MM; Thalgott M; Schmid SC; Oh WK; Gong Y; Wang L; Zhu J; Seitz AK; Porst D; Höppner M; Retz M; Gschwend JE; Nawroth R
    Prostate; 2016 Sep; 76(13):1160-8. PubMed ID: 27198487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets.
    Murtojärvi M; Halkola AS; Airola A; Laajala TD; Mirtti T; Aittokallio T; Pahikkala T
    Int J Med Inform; 2020 Jan; 133():104014. PubMed ID: 31783311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.
    Xie W; Stopsack KH; Drouin SJ; Fu H; Pomerantz MM; Mucci LA; Lee GM; Kantoff PW
    Prostate; 2019 Jan; 79(1):73-80. PubMed ID: 30141208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.
    Seyednasrollah F; Koestler DC; Wang T; Piccolo SR; Vega R; Greiner R; Fuchs C; Gofer E; Kumar L; Wolfinger RD; Kanigel Winner K; Bare C; Neto EC; Yu T; Shen L; Abdallah K; Norman T; Stolovitzky G; Soule HR; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Elo LL; Zhou FL; Guinney J; Costello JC;
    JCO Clin Cancer Inform; 2017 Nov; 1():1-15. PubMed ID: 30657384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
    Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
    Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of a Machine Learning Algorithm Using Electronic Health Record Data to Predict Postoperative Complications and Report on a Mobile Platform.
    Ren Y; Loftus TJ; Datta S; Ruppert MM; Guan Z; Miao S; Shickel B; Feng Z; Giordano C; Upchurch GR; Rashidi P; Ozrazgat-Baslanti T; Bihorac A
    JAMA Netw Open; 2022 May; 5(5):e2211973. PubMed ID: 35576007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland.
    Baillie K; Mueller T; Pan J; Laskey J; Bennie M; Crearie C; Kavanagh K; Alvarez-Madrazo S; Morrison D; Clarke J; Keel A; Cameron D; Wu O; Kurdi A; Jones RJ
    Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):653-663. PubMed ID: 32316077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Armstrong AJ; Anand A; Edenbrandt L; Bondesson E; Bjartell A; Widmark A; Sternberg CN; Pili R; Tuvesson H; Nordle Ö; Carducci MA; Morris MJ
    JAMA Oncol; 2018 Jul; 4(7):944-951. PubMed ID: 29799999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
    Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
    Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.